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Sacred Encounters Perfect Care Healthiest Communities

Disclosure
• Speakers’ Bureau: BMS, Merck.
• Advisory Meetings: Abbvie, Genentech.

Objectives
• Learn immune checkpoint inhibitor’s
(immunotherapy) mechanism of action.
• Recognize the differences in immunotherapy
side effects vs chemotherapy side effects.
• Learn initial management of immunotherapy
side effects.
• Learn about the resources available for
immunotherapy side effect management.

What is Immunotherapy?
• A type of therapy that affects the immune
system to fight cancer.
• Many different types of immunotherapy:
vaccines, small molecule compounds,
monoclonal antibodies, gene therapies,
cellular therapies.
• For the purpose of this talk, I will use the
terms “Immunotherapy” and “Immune
Checkpoint Inhibitors” interchangeably.

Immune Checkpoint Inhibitor
Mechanisms of Action

Suzanne L. Toaplian, et al. Nature Reviews Cancer volume 16, pages 275–287 (2016)

Immune Checkpoint Blockade:
Mechanism of Action

T cell
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FDA approved Agents and Indications
• Ipilimumab (CTLA-4 ab)
• Cemiplimab-rwlc, Nivolumab, Pebrolizumab
(PD-1 ab)
• Atezolizumab, Avelumab, Durvalumab (PD-L1
ab)
• More than 30 FDA approved Indications across
multiple cancer types, and GROWING!

Immunotherapy is better
tolerated

Severe Side Effects are Rare
but Do Occur

Immune side effects can involve Any
Organ

Immune side effects are usually delayed
in onset, unlike chemotherapy

Journal of Clinical Oncology 30(21):2691-2697.

Colitis was the most common serious side effect but
Myocardititis was most lethal by percentage

American Society of Clinical
Oncology(ASCO) 2018 Guideline
• Education prior to and throughout and after treatment.
• High level of suspicion for immune side effects
• Grade 2 toxicity: hold immunotherapy and start
corticosteroid (0.5-1mg/kg).
• Grade 3 toxicity: hold and start higher dose corticosteroid (12mg/kg IV). Consider adding infliximab or other
immunomodulators if no improvement in 48-72hrs.
• Grade 4 toxicity: similar to grade 3 toxicity management plus
permanent discontinuation.

Important to Slowly Taper
Corticosteroid!
• Need to taper prednisone slowly over 4-6
weeks to prevent relapse.
• Depending on the initial severity of immune
side effect, Immunotherapy may be resumed
when side effects improve to grade 1 and daily
prednisone dose of <10mg/day

Patient Education Video

Courtesy of Enza Nguyen, RN, MSN, ANP-BC

Courtesy of Enza Nguyen, RN, MSN, ANP-BC

Include in the Past Medical History
Section of Medical Record
• Immune-related adverse events can occur
even months after treatment has been
discontinued.
• Part of the differential diagnosis when
patients get sick.

Free Tools for immune side effect
management: NCCN Guidelines

www.nccn.org

Free Tools for immune side effect
management: ONCOASSIST

www.oncoassist.com

Conclusion
• Immune Checkpoint Inhibitors have revolutionized
Cancer treatment, and the use is expected to grow
over time.
• Immune side effects are usually manageable with
prompt recognition and corticosteroid use.
• Immune side effects can occur even after treatment
as been discontinued.
• Adherence to guidelines optimize immune side
effects management.

